Good MorningThis week, the market faces new challenges with President Donald Trump ratcheting pressure on trading partners, including China and the E.U. However, last week's S&P 500 index action suggests the market is resilient and can withstand the swings as it awaits the outcome. The question is whether the economy can withstand the impact of tariffs and ward off a recession. The FOMC can not be counted on for help, choosing not to act preemptively, leaving the market and investors in limbo.
This week could be a turning point for the market. Macroeconomic factors aside, NVIDIA is scheduled to report on Wednesday evening. The AI powerhouse is expected to post substantial growth, including outperformance relative to consensus estimates. The real question is how the deals with Saudi Arabia's HUMAIN have impacted the company's outlook and if they appear in the guidance. If so, NVIDIA stock will likely set a new all-time high, leading the AI complex and broad market to do the same. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Consumer Staples | |
Investors must always understand where they are in the stock market cycle. This is easier said than done, as all the noise can often blind participants to what they should be looking into and thinking about as well. However, occasionally, a certain indicator flashes to give investors an idea of wh... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Technology | | Today’s market is highly reactive to headlines, and understandably so. With major developments emerging almost weekly, it’s no surprise investors stay glued to their newswires as the S&P 500 swings in all directions. However useful this may be, the awareness part, there is also a cav... Read the Full Story |
|
Technology | |
After posting what was likely its worst earnings report ever in Q4 2024, Trade Desk (NASDAQ: TTD) roared back with a vengeance in Q1 2025. The communication services company’s final report for 2024 saw it miss internal expectations on revenue for the first time in 33 quarters. Overall, it ... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Business Services | |
Markets hate uncertainty, and so do companies that rely heavily on the government for a good deal of their business. Booz Allen Hamilton Holding Corp. (NYSE: BAH) generates approximately 97% of its revenue from the federal government, which explains the BAH stock's total return of over 500% in the... Read the Full Story |
|
Markets | |
Investors have ample reason to be concerned about the future of U.S. investment vehicles—mid-May's news of Moody's downgrade of the nation's credit rating and the resultant market shake-up and the lingering threat of dramatic tariff increases chief among them. Unsurprisingly, then, many inve... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Medical | |
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking investors.
Such a substantial return often signals a mature, stable company generously rewarding its shareholders. However, a closer look reveals a co... Read the Full Story |
|
Medical | | Whether or not members of Congress should be allowed to buy or sell stocks is another topic. Retail investors should keep their eyes on the ball. That means, if investors can’t beat them, they may be wise to join them.
Members of Congress have access to information that retail investors lack.... Read the Full Story |
|
Retail/Wholesale | |
TJX Companies (NYSE: TJX) stock price stumbled in the wake of its Q1 earnings report and guidance update, but investors should not fret. The move is a natural market movement within an otherwise bullish trend caused by tepidness in the result report.
The results were better than expected, with ... Read the Full Story |
|
Retail/Wholesale | |
Williams-Sonoma (NYSE: WSM) is fundamentally a good buy because of its operational quality, fortress balance sheet, cash flow, and ability to sustain value-building capital returns. It is on sale in Q2 2025 because the guidance update provides no catalyst for a rally. The guidance was reaffirmed t... Read the Full Story |
|
Retail/Wholesale | |
Advance Auto Parts Inc. (NYSE: AAP) is giving investors a big, beautiful return of over 50% after the company reported a double beat on earnings. The auto parts retailer also said it maintained its full-year forecast despite the uncertain tariff outlook. As of noon on May 22, AAP stock was up 53.5... Read the Full Story |
|
Monday's Early Bird Stock Of The Day We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California. | | View Today's Stock Pick |
|
